Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 6
1997 8
1998 15
1999 19
2000 27
2001 24
2002 21
2003 17
2004 25
2005 15
2006 18
2007 15
2008 12
2009 8
2010 10
2011 12
2012 9
2013 11
2014 5
2015 6
2016 12
2017 9
2018 7
2019 6
2020 4
2021 2
2022 2
2023 4
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Results by year

Filters applied: . Clear all
Page 1
Acute Migraine Treatment in Adults.
Becker WJ. Becker WJ. Headache. 2015 Jun;55(6):778-93. doi: 10.1111/head.12550. Epub 2015 Apr 15. Headache. 2015. PMID: 25877672 Review.
Acetaminophen, 4 nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, acetylsalicylic acid [ASA], naproxen sodium, and diclofenac potassium), and 7 triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan) have good evid …
Acetaminophen, 4 nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, acetylsalicylic acid [ASA], naproxen sodium, and diclofenac potas …
The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.
Marmura MJ, Silberstein SD, Schwedt TJ. Marmura MJ, et al. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499. Headache. 2015. PMID: 25600718 Review.
The specific medications - triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan [oral, nasal spray, injectable, transcutaneous patch], zolmitriptan [oral and nasal spray]) and dihydroergotamine (nasal spray, inhaler) are effective (Level A …
The specific medications - triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan [oral, nasal spray, …
Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Yang CP, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544. JAMA Netw Open. 2021. PMID: 34633423 Free PMC article.
Lasmiditan was associated with the highest risk of any adverse events, and certain triptans (rizatriptan, sumatriptan, and zolmitriptan) were also associated with a higher risk of any adverse events than the calcitonin gene-related peptide antagonists. ...
Lasmiditan was associated with the highest risk of any adverse events, and certain triptans (rizatriptan, sumatriptan, and zolmitript …
Rizatriptan in migraine.
Krymchantowski AV, Bigal ME. Krymchantowski AV, et al. Expert Rev Neurother. 2005 Sep;5(5):597-603. doi: 10.1586/14737175.5.5.597. Expert Rev Neurother. 2005. PMID: 16162083 Review.
However, they differ with regard to several of their clinical parameters, including onset of relief and consistency of response. Rizatriptan is a selective agonist of the 5-hydroxytryptophan(1B/1D )receptors, with proven superiority over placebo, ergotamine and selected or …
However, they differ with regard to several of their clinical parameters, including onset of relief and consistency of response. Rizatrip …
Rizatriptan: an update of its use in the management of migraine.
Wellington K, Plosker GL. Wellington K, et al. Drugs. 2002;62(10):1539-74. doi: 10.2165/00003495-200262100-00007. Drugs. 2002. PMID: 12093318 Review.
Rizatriptan is generally well tolerated and adverse events are usually mild and transient. ...Although well designed studies comparing rizatriptan with almotriptan, eletriptan and frovatriptan would further define the position of rizatriptan, current data sug …
Rizatriptan is generally well tolerated and adverse events are usually mild and transient. ...Although well designed studies comparin …
Spotlight on rizatriptan in migraine.
Wellington K, Jarvis B. Wellington K, et al. CNS Drugs. 2002;16(10):715-20. doi: 10.2165/00023210-200216100-00005. CNS Drugs. 2002. PMID: 12269863 Review.
Rizatriptan is generally well tolerated, and adverse events are usually mild and transient. ...Although well designed studies comparing rizatriptan with almotriptan, eletriptan and frovatriptan would further define the position of rizatriptan, current data su …
Rizatriptan is generally well tolerated, and adverse events are usually mild and transient. ...Although well designed studies compari …
[Rizatriptan].
Leira R, Pascual J. Leira R, et al. Neurologia. 2000 Jan;15(1):22-30. Neurologia. 2000. PMID: 10730063 Review. Spanish. No abstract available.
Aquaporin-Targeted Therapeutics: State-of-the-Field.
Tradtrantip L, Jin BJ, Yao X, Anderson MO, Verkman AS. Tradtrantip L, et al. Adv Exp Med Biol. 2017;969:239-250. doi: 10.1007/978-94-024-1057-0_16. Adv Exp Med Biol. 2017. PMID: 28258578 Free PMC article. Review.
Rizatriptan: pharmacological differences from sumatriptan and clinical results.
Lines CR, McCarroll KA, Visser WH. Lines CR, et al. Curr Med Res Opin. 2001;17 Suppl 1:s54-8. doi: 10.1185/0300799039117015. Curr Med Res Opin. 2001. PMID: 12463279 Review.
For oral formulations, the time to maximum plasma concentration is reached earlier with rizatriptan than with sumatriptan (1 h versus 2-2.5 h) and rizatriptan has greater bioavailability than sumatriptan (45% versus 15%). ...Rizatriptan 10 mg was generally su …
For oral formulations, the time to maximum plasma concentration is reached earlier with rizatriptan than with sumatriptan (1 h versus …
Comparison table: Triptans.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-e99. doi: 10.58347/tml.2023.1678b. Med Lett Drugs Ther. 2023. PMID: 37266988 No abstract available.
315 results